The store will not work correctly when cookies are disabled.
Home
Products
Product Types
Cell Culture Media and Supplements
StemSpan™ CC110
StemSpan™ CC110 Serum-free culture supplement for expansion of human hematopoietic cells Skip to the end of the images gallery Skip to the beginning of the images gallery StemSpan™ CC110 Serum-free culture supplement for expansion of human hematopoietic cells Request PricingSize Choose an Option... 1 mL Request Pricing Size 1 mLCatalog # (Select a product) Serum-free culture supplement for expansion of human hematopoietic cells Quantity Add to Cart Request Pricing
By submitting this form, you are providing your consent to STEMCELL Technologies Canada Inc. and its subsidiaries and affiliates (“STEMCELL”) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
Request Pricing
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to STEMCELL Technologies Canada Inc. and its subsidiaries and affiliates (“STEMCELL”) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
First Name Last Name
Work Email Address Phone Number
Company/Institution Zip/Postal Code
Country Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegowina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic East Timor Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France France, Metropolitan French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guinea Guinea-Bissau Guyana Haiti Heard and Mc Donald Islands Honduras Hong Kong Hungary Iceland India Indonesia Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati Korea, Republic of Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States of Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar (Burma) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Republic of Serbia Reunion Romania Russia Rwanda Saint Kitts and Nevis Saint Lucia Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Seychelles Sierra Leone Singapore Slovakia (Slovak Republic) Slovenia Solomon Islands Somalia South Africa South Georgia and South S.S. Spain Sri Lanka St. Helena St. Pierre and Miquelon Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Taiwan Tajikistan Tanzania, United Republic of Thailand The Democratic Republic of Congo Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu U.S. Minor Islands Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City State Venezuela Vietnam Virgin Islands (British) Virgin Islands (U.S.) Wallis and Futuna Islands Western Sahara Yemen Zambia Zambrazo Zimbabwe State/Province/Region
Comment
I agree to receive future electronic communications from STEMCELL. I acknowledge that I can unsubscribe any time.
Overview Protocols and Documentation Applications Resources and Publications Related Products
Overview
StemSpan™ CC110 contains a combination of early-acting recombinant human (rh) cytokines formulated to support the proliferation of human hematopoietic cells. It is supplied as a 100X concentrate. When added to serum-free medium, StemSpan™ CC110 promotes the expansion of CD34+ cells isolated from human cord blood and bone marrow. StemSpan™ CC110 stimulates similar expansion of CD34+ cells compared to StemSpan™ CC100, but with higher purity and is meant for use in short-term cultures to activate stem cell and immature progenitor cycling, without necessarily promoting the proliferation and differentiation of later progenitors. We recommend using StemSpan™ CC110 in combination with any of the following StemSpan™ media: • StemSpan™ SFEM (Catalog #09600) • StemSpan™ SFEM II (Catalog #09605) • StemSpan™-XF (Catalog #100-0073) • StemSpan™-AOF (Catalog #100-0130) Contains • Recombinant human fms-like tyrosine kinase 3 ligand (Flt3L) • Recombinant human stem cell factor (SCF) • Recombinant human thrombopoietin (TPO) Subtype Supplements Cell Type Hematopoietic Stem and Progenitor Cells Species Human Application Cell Culture, Expansion Brand StemSpan Area of Interest Stem Cell Biology, Transplantation Research Formulation Category Serum-Free View More View Less
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
Document Type Product Name Catalog # Lot # Language Document Type Product Information Sheet Product Name StemSpan™ CC110 Catalog # 02697 Lot # All Language English Document Type Safety Data Sheet Product Name StemSpan™ CC110 Catalog # 02697 Lot # All Language English View More View Less
Applications
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Research AreaWorkflow StagesWorkflow Stages for Hematopoietic Stem and Progenitor Cell Research Cell Sourcing and IsolationExpansion and DifferentiationAnalysis View More View Less
Resources and Publications
Educational Materials (6)
Brochure Hematopoietic Stem and Progenitor Cells - Products for Your Research Brochure StemSpan™: Defined Media and Supplements for Hematopoietic Cell Expansion 1:51 Video StemSpan™ Serum-Free Expansion Media 1:06:52 Webinar New Tools for the Ex Vivo Expansion of Human Hematopoietic Stem and Progenitor Cells 55:51 Webinar CRISPR-Cas9 Editing of Hematopoietic Stem and Progenitor Cells Mini Review Hematopoietic Stem and Progenitor Cells (HSPCs): Isolation, Culture, and Assays
Publications (13)
Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. M. A. DeWitt et al. Science translational medicine 2016 OCT
Abstract
Genetic diseases of blood cells are prime candidates for treatment through ex vivo gene editing of CD34+ hematopoietic stem/progenitor cells (HSPCs), and a variety of technologies have been proposed to treat these disorders. Sickle cell disease (SCD) is a recessive genetic disorder caused by a single-nucleotide polymorphism in the $\beta$-globin gene (HBB). Sickle hemoglobin damages erythrocytes, causing vasoocclusion, severe pain, progressive organ damage, and premature death. We optimize design and delivery parameters of a ribonucleoprotein (RNP) complex comprising Cas9 protein and unmodified single guide RNA, together with a single-stranded DNA oligonucleotide donor (ssODN), to enable efficient replacement of the SCD mutation in human HSPCs. Corrected HSPCs from SCD patients produced less sickle hemoglobin RNA and protein and correspondingly increased wild-type hemoglobin when differentiated into erythroblasts. When engrafted into immunocompromised mice, ex vivo treated human HSPCs maintain SCD gene edits throughout 16 weeks at a level likely to have clinical benefit. These results demonstrate that an accessible approach combining Cas9 RNP with an ssODN can mediate efficient HSPC genome editing, enables investigator-led exploration of gene editing reagents in primary hematopoietic stem cells, and suggests a path toward the development of new gene editing treatments for SCD and other hematopoietic diseases. View publication Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity. Karpinski J et al. Nature Biotechnology 2016 APR
Abstract
Current combination antiretroviral therapies (cART) efficiently suppress HIV-1 reproduction in humans, but the virus persists as integrated proviral reservoirs in small numbers of cells. To generate an antiviral agent capable of eradicating the provirus from infected cells, we employed 145 cycles of substrate-linked directed evolution to evolve a recombinase (Brec1) that site-specifically recognizes a 34-bp sequence present in the long terminal repeats (LTRs) of the majority of the clinically relevant HIV-1 strains and subtypes. Brec1 efficiently, precisely and safely removes the integrated provirus from infected cells and is efficacious on clinical HIV-1 isolates in vitro and in vivo, including in mice humanized with patient-derived cells. Our data suggest that Brec1 has potential for clinical application as a curative HIV-1 therapy. View publication PPAR-α and glucocorticoid receptor synergize to promote erythroid progenitor self-renewal. Lee H-Y et al. Nature 2015 JUN
Abstract
Many acute and chronic anaemias, including haemolysis, sepsis and genetic bone marrow failure diseases such as Diamond-Blackfan anaemia, are not treatable with erythropoietin (Epo), because the colony-forming unit erythroid progenitors (CFU-Es) that respond to Epo are either too few in number or are not sensitive enough to Epo to maintain sufficient red blood cell production. Treatment of these anaemias requires a drug that acts at an earlier stage of red cell formation and enhances the formation of Epo-sensitive CFU-E progenitors. Recently, we showed that glucocorticoids specifically stimulate self-renewal of an early erythroid progenitor, burst-forming unit erythroid (BFU-E), and increase the production of terminally differentiated erythroid cells. Here we show that activation of the peroxisome proliferator-activated receptor α (PPAR-α) by the PPAR-α agonists GW7647 and fenofibrate synergizes with the glucocorticoid receptor (GR) to promote BFU-E self-renewal. Over time these agonists greatly increase production of mature red blood cells in cultures of both mouse fetal liver BFU-Es and mobilized human adult CD34(+) peripheral blood progenitors, with a new and effective culture system being used for the human cells that generates normal enucleated reticulocytes. Although Ppara(-/-) mice show no haematological difference from wild-type mice in both normal and phenylhydrazine (PHZ)-induced stress erythropoiesis, PPAR-α agonists facilitate recovery of wild-type but not Ppara(-/-) mice from PHZ-induced acute haemolytic anaemia. We also show that PPAR-α alleviates anaemia in a mouse model of chronic anaemia. Finally, both in control and corticosteroid-treated BFU-E cells, PPAR-α co-occupies many chromatin sites with GR; when activated by PPAR-α agonists, additional PPAR-α is recruited to GR-adjacent sites and presumably facilitates GR-dependent BFU-E self-renewal. Our discovery of the role of PPAR-α agonists in stimulating self-renewal of early erythroid progenitor cells suggests that the clinically tested PPAR-α agonists we used may improve the efficacy of corticosteroids in treating Epo-resistant anaemias. View publication View All Publications
Related Products
Related Products
StemSpan™ CD34+ Expansion Supplement (10X)
Serum-free culture supplement for expansion of human CD34+ hematopoietic cells
StemSpan™ SFEM
Serum-free medium for culture and expansion of hematopoietic cells
StemSpan™ SFEM II
Serum-free medium for culture and expansion of hematopoietic cells
Item added to your cart
StemSpan™ CC110
Quality Statement: PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
Skip to the beginning of the images gallery StemSpan™ CC110 Serum-free culture supplement for expansion of human hematopoietic cells Size Choose an Option... 1 mL Request Pricing Size 1 mL Catalog # (Select a product) Serum-free culture supplement for expansion of human hematopoietic cells Quantity Add to Cart Request Pricing 
Brochure Hematopoietic Stem and Progenitor Cells - Products for Your Research 
Brochure StemSpan™: Defined Media and Supplements for Hematopoietic Cell Expansion 
1:51 Video StemSpan™ Serum-Free Expansion Media 
1:06:52 Webinar New Tools for the Ex Vivo Expansion of Human Hematopoietic Stem and Progenitor Cells 
55:51 Webinar CRISPR-Cas9 Editing of Hematopoietic Stem and Progenitor Cells 
Mini Review Hematopoietic Stem and Progenitor Cells (HSPCs): Isolation, Culture, and Assays 
Loading...